The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies
- 1Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
- 2Department of Medical Gastroenterology, Odense University Hospital, Odense, Denmark
- Correspondence to:
Professor N J Talley, Department of Medicine, University of Sydney, Nepean Hospital, Penrith 2751, NSW, Australia;
ntalley{at}blackburn.med.su.oz.au
Abstract
Dyspepsia is a common condition in the general population but data are lacking on the benefits of effective acid inhibition with proton pump inhibitors in functional dyspepsia. The results of the large, randomised, double blind clinical trials, BOND and OPERA, the Scandinavian PILOT study, and a follow up study, ENCORE, are reviewed. BOND, OPERA, and PILOT aimed to address the question of whether effective acid inhibition with the proton pump inhibitor omeprazole relieves symptoms in patients with functional dyspepsia. ENCORE followed on from this, addressing the consequences of relieving symptoms in patients with functional dyspepsia once they are off therapy.
- GORD, gastro-oesophageal reflux disease
- GSRS, gastrointestinal symptom rating scale
- ITT, intention to treat
- MBS, most bothersome symptom
- PGWB, psychological general well being
Footnotes
-
Conflict of interest: This symposium was sponsored by AstraZeneca, makers of omeprazole. The authors of this paper have received sponsorship for travel and an honorarium from AstraZeneca.
NJ Talley has been a consultant and received research grants fromTAP, Takeda, Ledede, Pharmacia, and Janssen
